Amgen and AstraZeneca's Tezspire Shows Promise in Eosinophilic Esophagitis Trial

Pharmaceutical companies Amgen and AstraZeneca have announced positive results from a Phase 3 trial evaluating Tezspire (tezepelumab-ekko) for treating eosinophilic esophagitis. The CROSSING trial met its co-primary endpoints at week 24, measuring histologic remission and dysphagia symptom improvement, with results sustained through week 52.

The trial enrolled 368 patients aged 12-80 years with symptomatic and histologically active eosinophilic esophagitis who were randomized to receive either low or high dose Tezspire or placebo subcutaneously every four weeks. Histologic remission was defined as a peak esophageal eosinophil count of six or fewer eosinophils per high-power field.

The safety profile was consistent with Tezspire's approved indications for severe asthma and chronic rhinosinusitis with nasal polyps. Eosinophilic esophagitis affects more than 470,000 people in the U.S., with prevalence increasing five-fold since 2009.